Derivative spectrophotometric and fluorimetric methods for determination of rofecoxib in tablets and in human plasma in presence of its photo-degradation product.
Rofecoxib (I) has been determined in the presence of its photo-degradation product (II) using first derivative spectrophotometry ((1)D) and first derivative of the ratio spectra ((1)DD) by measuring the amplitude at 316.3 and 284 nm for (1)D and (1)DD, respectively. (I) can be determined in the presence of up to 70% and 80% of (II) by the (1)D and (1)DD, respectively. The linearity range of both the methods was the same (5.8-26.2 microg ml(-1)) with mean percentage recovery of 100.08 +/- 0.84 and 100.06 +/- 1.06 for (1)D and (1)DD, respectively. (1)D method was used to study kinetics of (I) photo-degradation that was found to follow a first-order reaction. The t(1/2) was 20.2 min while K (reaction rate constant) was 0.0336 mol min(-1). Both methods were applied to the analysis of (I) in bulk powder and in pharmaceutical formulations. Also a spectrofluorimetric method is described to determine (I) at very low concentrations (25-540 ng ml(-1)) where (I) is converted to its photo-degradate (II), which possesses a native fluorescence that could be measured. The proposed method was applied for the analysis of tablets containing rofecoxib as well as to rofecoxib-spiked human plasma.